16204712

Source:http://linkedlifedata.com/resource/pubmed/id/16204712

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0031268, umls-concept:C0031809, umls-concept:C0032743, umls-concept:C0205210, umls-concept:C0237401, umls-concept:C0314603, umls-concept:C0560005, umls-concept:C0681842, umls-concept:C1274040, umls-concept:C1704970
pubmed:issue	10
pubmed:dateCreated	2005-10-5
pubmed:abstractText	Patients with mild cognitive impairment (MCI) represent a risk population for progressing to dementia of the Alzheimer type (DAT). However, clinical criteria do not ensure reliable individual prognosis in these patients. The objective of this longitudinal, prospective study was to examine the value of (18)F-FDG PET of cerebral glucose metabolism and of genetic susceptibility, as defined by an APOEepsilon4-positive genotype, with regard to the early diagnosis of DAT in patients with MCI.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0217410
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Apolipoproteins E, http://linkedlifedata.com/resource/pubmed/chemical/Fluorodeoxyglucose F18, http://linkedlifedata.com/resource/pubmed/chemical/Radiopharmaceuticals
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	0161-5505
pubmed:author	pubmed-author:AlexopoulusPanagiotisP, pubmed-author:DrzezgaAlexanderA, pubmed-author:GrimmerTimoT, pubmed-author:KurzAlexanderA, pubmed-author:LautenschlagerNicolaN, pubmed-author:MinoshimaSatoshiS, pubmed-author:RiemenschneiderMatthiasM, pubmed-author:SchwaigerMarkusM, pubmed-author:SiebnerHartwigH
pubmed:issnType	Print
pubmed:volume	46
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1625-32
pubmed:dateRevised	2009-11-19
pubmed:meshHeading	pubmed-meshheading:16204712-Aged, pubmed-meshheading:16204712-Alzheimer Disease, pubmed-meshheading:16204712-Apolipoproteins E, pubmed-meshheading:16204712-Cognition Disorders, pubmed-meshheading:16204712-Female, pubmed-meshheading:16204712-Fluorodeoxyglucose F18, pubmed-meshheading:16204712-Genetic Predisposition to Disease, pubmed-meshheading:16204712-Genetic Testing, pubmed-meshheading:16204712-Humans, pubmed-meshheading:16204712-Male, pubmed-meshheading:16204712-Phenotype, pubmed-meshheading:16204712-Positron-Emission Tomography, pubmed-meshheading:16204712-Prognosis, pubmed-meshheading:16204712-Radiopharmaceuticals, pubmed-meshheading:16204712-Reproducibility of Results, pubmed-meshheading:16204712-Risk Assessment, pubmed-meshheading:16204712-Risk Factors, pubmed-meshheading:16204712-Sensitivity and Specificity
pubmed:year	2005
pubmed:articleTitle	Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.
pubmed:affiliation	Department of Nuclear Medicine, Technische Universität, München, Munich, Germany. a.drzezga@lrz.tu-muenchen.de
pubmed:publicationType	Journal Article, Controlled Clinical Trial